KOSDAQBiotech & Pharma307750

Kukjeon

₩1,851▼ 0.48%2026-11-18 close
Market Cap
₩99.9B
Turnover
₩200M
Volume
80K
Shares out.
54M
PER
325.7×
PBR
0.9×
EPS
₩6
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Materials Expansion Amid a Profit Recovery Test

Kukjeon pairs pharmaceutical APIs with electronic materials, and its 2026 quarterly profit swings sit against a full-year 2025 loss, with attributable net profit of only KRW 297 million over the last four quarters.

  1. 1

    Full-year 2025 revenue was KRW 131 billion, down 4.0% year on year, with an operating loss of KRW 2.58 billion and an attributable net loss of KRW 4.3 billion.

  2. 2

    Attributable net profit turned positive in Q2 2026 at KRW 6.11 billion, but Q3 2026 returned to an operating loss of KRW 676 million.

  3. 3

    The materials business is described as contributing to profitability through high-purity additives for HBM manufacturing and OLED materials.

  4. 4

    Private convertible bonds totaling KRW 17 billion become convertible from November 2, 2027, and could issue 6,305,637 common shares.

  5. 5

    The largest shareholder group holds 52.23%, and the free float ratio is 47.77%.

02

Business structure

Kukjeon was founded in 1995 and listed on KOSDAQ in 2020, operating across two segments: pharmaceuticals and materials. The pharmaceutical segment handles synthesis, import distribution and sales of active pharmaceutical ingredients, mainly supplying drug makers and API companies.

The materials segment covers advanced materials for OLED, next-generation displays, AI-oriented semiconductor packaging and automotive electronics.

Building on its core chemical synthesis capability, the company has extended into OLED materials, semiconductor materials and electrolyte additives for secondary batteries, and completed an electronic materials plant in Eumseong, Chungbuk in August 2023.

At the March 31, 2026 shareholders meeting, the company changed its name from Kukjeon Pharmaceutical to Kukjeon and revised its business purpose to fine chemical materials manufacturing and sales.

Its subsidiaries include Enisolution (oral formulation technology), KS Biologics (nanoparticle anticancer drugs) and Kukjeon F&D (AI-based regulatory compliance software).

A corporate monitoring summary as of June 8, 2026 said high-purity additives for HBM manufacturing and OLED material supply contributed to profitability, and that the pharmaceutical segment maintains a firm position in the API market. The largest shareholder group holds 52.23% as of September 2, 2026, and the free float ratio is 47.77%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩29.2B-₩2B−7.0%
2025Q4₩30.2B₩100M0.4%
2026Q1₩34.7B₩2.7B7.7%
2026Q2₩40.5B₩1.5B3.7%
2026Q3₩31.3B-₩700M−2.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩103.7B₩3.5B₩8.9B3.4%9.8%112.4%
2023₩122B₩6.5B₩4.8B5.3%5.0%131.0%
2024₩136.5B₩400M₩1.7B0.3%1.8%117.7%
2025₩131B-₩2.6B-₩4.3B−2.0%−4.5%86.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 103.7 billion in 2022 to KRW 122 billion in 2023 (up 17.6%) and KRW 136.5 billion in 2024 (up 11.9%), then fell to KRW 131 billion in 2025 (down 4.0%). Among 2022 to 2025, 2024 was the largest year and 2022 the smallest.

Operating profit went from KRW 3.51 billion in 2022 to KRW 6.5 billion in 2023 (up 85.2%), then dropped to KRW 368 million in 2024 (down 94.3%), and 2025 turned into an operating loss of KRW 2.58 billion.

The operating margin was 3.4% in 2022, 5.3% in 2023, 0.3% in 2024 and -2.0% in 2025, so even in 2024, the largest revenue year, the margin stayed at 0.3%.

Attributable net profit was KRW 8.95 billion in 2022, KRW 4.82 billion in 2023 (down 46.1%) and KRW 1.74 billion in 2024 (down 64.0%), and 2025 turned into an attributable net loss of KRW 4.3 billion.

Net income including non-controlling interests was a loss of KRW 4.82 billion in 2025, a different figure from the attributable result. Operating cash flow moved from negative in 2022 and 2023 to KRW 10 billion in 2024 and KRW 10.6 billion in 2025. The debt-to-equity ratio fell from 117.7% in 2024 to 86.9% in 2025.

At the end of 2025, total equity was KRW 95.9 billion, attributable equity was KRW 96.3 billion and total liabilities were KRW 83.3 billion, so attributable equity exceeded total equity, implying a negative non-controlling interest.

Quarterly, Q3 2025 revenue of KRW 29.2 billion came with an operating loss of KRW 2.03 billion, and Q4 2025 revenue of KRW 30.2 billion (up 3.4% quarter on quarter) produced an operating profit of KRW 136 million.

Q1 2026 revenue was KRW 34.7 billion (up 14.8% quarter on quarter) with operating profit of KRW 2.66 billion (up 1,864.1%), yet attributable net loss was KRW 2.66 billion, and market data put non-operating items at about minus KRW 4.17 billion in that quarter.

Q2 2026 revenue was KRW 40.5 billion (up 16.8%) with operating profit of KRW 1.5 billion (down 43.8%), and attributable net profit of KRW 6.11 billion turned positive, with market data showing non-operating income of KRW 7.004 billion.

Q3 2026 revenue was KRW 31.3 billion (down 22.7% quarter on quarter, up 7.1% year on year), with an operating loss of KRW 676 million and an attributable net loss of KRW 746 million.

Over the last four quarters, attributable net profit totaled KRW 297 million, and quarterly profit moves largely with non-operating items.

05

Industry analysis

Kukjeon sits in the biopharma sector, but its business is split between APIs and electronic and semiconductor materials, so its structure differs from biologics-focused listed peers.

The pharmaceutical segment centers on synthesis and import distribution of active ingredients, so chemical synthesis capability is the basis of its competitiveness, unlike companies centered on finished drugs or biologics production.

The materials segment targets OLED, next-generation displays and AI-oriented semiconductor packaging, so its results depend on customer investment and process adoption in display and chip makers.

A corporate monitoring summary said high-purity additives for HBM manufacturing and OLED material supply contributed to profitability in Q1 2026. The same summary described the pharmaceutical segment as maintaining a firm position in the API market.

Changing the business purpose at the March 2026 shareholders meeting to fine chemical materials manufacturing signals that the company is building materials into a formal business line. Shifts in the customer mix and revenue share of the materials segment will shape the company's position within its sector.

The Eumseong plant, completed in August 2023, is the production base for electronic materials. With a market capitalization of about KRW 105.5 billion, the stock is small in size, so company disclosures and trading flows can move the share price relatively strongly.

06

Outlook

The company's medium-term direction is visible in its revised business purpose, which now covers fine chemical materials manufacturing and sales. It is extending into semiconductor packaging materials, and whether HBM additive supply continues to lift profitability is the next thing to watch.

The Eumseong electronic materials plant was completed in August 2023, and whether its capacity translates into higher utilization can be checked in the business report's production section.

The company said all proceeds of the KRW 17 billion fourth private convertible bond will go to debt repayment, and payment was completed on November 2, 2026.

Market data show interest expense falling from KRW 1.219 billion in Q3 2025 to KRW 874 million in Q2 2026, and how far debt repayment sustains that trend will shape non-operating results.

Conversion is possible from November 2, 2027 to October 2, 2031, and full conversion could issue 6,305,637 common shares, equal to 10.46% of the total shares outstanding at the time of the issuance decision.

In a recent large-holding report, an asset manager and related parties disclosed 5.91% including CB rights, with no common shares held according to the report. The next periodic report is the 2026 annual report, which will be the first to finalize Q4 2026 results.

The change of the English name to KUKJEON Co.,Ltd, adopted to reflect business expansion, will also show how prominently the materials push appears in external communication.

07

Valuation

PER
325.7×
PBR
0.9×
ROE
0.3%
EPS
₩6
BPS
₩2,114
Dividend per share
₩0

The price-to-book ratio sits below 1x, so the stock trades at a discount to book net assets. Attributable equity (KRW 96.3 billion) exceeds total equity (KRW 95.9 billion), which implies a negative non-controlling interest, and this structure should be considered in any net-asset comparison.

Earnings-based multiples are hard to compare with industry averages, because attributable net profit over the last four quarters totals only KRW 297 million. The dividend yield is below the industry average, and 2025 was a loss year, so earnings do not currently support a dividend.

If all the KRW 17 billion convertible bonds convert, about 6.3 million shares would be added, changing the share-count-based ownership structure. With the largest shareholder group holding 52.23% and a free float ratio of 47.77%, price sensitivity to trading flows is concentrated in the free-float base.

Non-operating swings strongly affect quarterly net profit, so comparing operating profit and attributable net profit separately is necessary.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Improving profitability in materials

A corporate monitoring summary as of June 8, 2026 said high-purity additives for HBM manufacturing and OLED material supply contributed to profitability. The company is expanding into advanced semiconductor packaging materials and revised its business purpose at the March 2026 shareholders meeting. How much of this shows up in revenue and profit can be gauged from segment information in the business report.

Quarterly profit recovery

Operating results moved from a KRW 2.03 billion operating loss in Q3 2025 to a KRW 136 million operating profit in Q4 2025. Operating profit then reached KRW 2.66 billion in Q1 2026, and attributable net profit of KRW 6.11 billion turned positive in Q2 2026. This sequence reads as evidence of quarterly earnings recovery.

Improving financial structure

The debt-to-equity ratio fell from 117.7% in 2024 to 86.9% in 2025. Operating cash flow stayed positive, at KRW 10 billion in 2024 and KRW 10.6 billion in 2025. The company said all proceeds of the KRW 17 billion convertible bond will go to debt repayment, which could reduce borrowing burden.

09

Bear factors

Annual loss swing

In 2025, revenue declined while both operating profit and attributable net profit turned to losses. The operating margin fell from 0.3% in 2024 to -2.0% in 2025. The annual figures show weaker earnings capacity.

Volatile quarterly profit

Q3 2026 returned to an operating loss of KRW 676 million and an attributable net loss of KRW 746 million. Attributable net profit over the last four quarters totals only KRW 297 million. Market data suggest the Q2 2026 profit was driven largely by non-operating income of KRW 7.004 billion.

Dilution and share structure

The KRW 17 billion private convertible bond could issue 6,305,637 common shares on conversion, equal to 10.46% of prior total shares outstanding. Conversion requests can be made from November 2, 2027.

The largest shareholder group holds 52.23% and the free float ratio is 47.77%, and an asset manager reported 5.91% including CB rights.

10

Risk factors

Convertible bond dilution

Conversion of the KRW 17 billion bond would add 6,305,637 common shares. Conversion is possible from November 2, 2027 through October 2, 2031, so per-share analysis must reflect both the size and the timing of conversion.

Dependence on downstream demand

Materials results depend on investment and process adoption by OLED, display and chip customers. Whether the contribution from HBM additives and OLED materials is a single-quarter effect or a sustained trend is not yet clear from the disclosed results. Customer-side changes can pass through to earnings quickly.

Non-operating swings

In Q1 2026, operating profit of KRW 2.66 billion coexisted with an attributable net loss of the same size, while Q2 net profit benefited from higher non-operating income. Quarterly net profit moves with non-operating items, so it can diverge from operating results. The share of one-time items such as asset sale gains also needs checking.

11

What to watch next

  1. After January 2027

    Check whether full-year 2026 results are disclosed and how Q4 operating profit and attributable net profit compare with the earlier trend. This is the starting point for judging the annual picture.

  2. Late March 2027

    The 2026 annual report will finalize Q4 results and full-year operating margin and attributable net profit as disclosed figures. It is the checkpoint for whether the operating margin recovers from the 2025 loss.

  3. After December 2026

    Check how the KRW 17 billion convertible bond proceeds are used for debt repayment and how interest expense trends. Whether interest costs fall matters for reducing the volatility of non-operating results.

  4. After November 2, 2027

    Conversion requests can begin on this date. The conversion volume of 6,305,637 common shares and actual conversion activity will affect the share-count-based ownership structure.

12

Overall view

Kukjeon combines a pharmaceutical API business with OLED and semiconductor materials, and the materials profitability gains are partly visible in 2026 quarterly results. On a full-year basis, 2025 recorded an operating loss of KRW 2.58 billion and an attributable net loss of KRW 4.3 billion, a swing into loss.

In 2026, quarterly results were mixed, with Q1 operating profit of KRW 2.66 billion, Q2 attributable net profit of KRW 6.11 billion after turning positive, and Q3 operating loss of KRW 676 million.

Attributable net profit over the last four quarters totals KRW 297 million, and the Q2 profit was driven heavily by higher non-operating income. On the financial side, the debt-to-equity ratio fell to 86.9% in 2025, and operating cash flow was positive in both 2024 and 2025.

Strengths include the materials expansion and the return to quarterly profit, while weaknesses include the full-year loss, convertible bond dilution risk and concentrated ownership by the largest shareholder group.

The next checkpoints are the 2026 annual report, which is due by late March 2027 and will finalize Q4 results, and whether conversion requests begin after November 2, 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.wisereport.co.kr
  2. k5.co.kr
  3. vegannews.co.kr
  4. digitaltoday.co.kr
  5. google.com
  6. news.nate.com
  7. m.news.nate.com
  8. vegannews.co.kr
  9. enertopianews.co.kr
  10. naewoeilbo.com
  11. dtoday.co.kr
  12. koreapressunion.com
  13. jninnews.com
  14. welfarehello.com
  15. biz.heraldcorp.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis